Apelin Fusion Proteins and Uses Thereof
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsPanayiotis Stevis, Andrew Murphy
Life of this patent
Estimating the term…
Abstract
The invention provides a fusion protein or polypeptide comprising an apelin peptide fused to a multimerizing component. The invention also provides a fusion protein or polypeptide comprising an apelin peptide fused to an Fc domain, a fragment of an Fc domain, or a variant of an Fc domain. Apelin Fc-fusion polypeptides are capable of binding to the apelin receptor (APLNR). Apelin Fc-fusion polypeptides are capable of activating the APLNR and have improved pharmacokinetic properties compared to apelin peptides that are not fused to an Fc or an Fc fragment. Apelin Fc-fusion polypeptides are useful in diseases and conditions related to cardiovascular function, diabetes, cancer, obesity and other apelin-related conditions.
Claims31
1-48. (canceled)
A polypeptide comprising an apelin peptide fused to an Fc domain, a fragment of an Fc domain, or variant of an Fc domain, wherein the N-terminus of the apelin peptide is fused to the C-terminus of the Fc domain or fragment or variant thereof, optionally via a peptide linker.
A polypeptide comprising the amino acid sequence of SEQ ID NO:
- 39.
A polypeptide comprising the amino acid sequence of SEQ ID NO:
- 40.
A polypeptide comprising the amino acid sequence of SEQ ID NO:
- 41.
Dependencies are inferred from the claim text.